Max India gets approval to sell 21% stake in Max GB to DSM
27 March 2001 12:49 [Source: ICIS news]
SINGAPORE (CNI)--India's Foreign Investment Promotion Board has given approval for pharmaceuticals group Max India to sell a 21% stake in its penicillin-manufacturing joint venture Max GB to partner DSM for Rs226.6m ($4.87m/Euro5.43m), a spokesman from Max India told CNI on Tuesday.
After the acquisition has been completed, Dutch chemicals and life sciences group DSM will own 95% of Max GB and Max India the remaining 5%.
Max GB's sales reached Rs2bn last year.
By: Staff Reporter
+44 20 8652 3214
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
| ICIS news FREE TRIAL |
| Get access to breaking chemical news as it happens. |
| ICIS Global Petrochemical Index (IPEX) |
| ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index |
Related Articles
- 08 Aug 03 08:13 Max India expands metalised BOPP plant in Rail Majra
- 01 Apr 03 02:24 India lifts restrictions on penicillin, rifampicin imports
- 06 Mar 00 00:00 Penicillin Market Plagued By Overcapacity and Pricing
- 28 Nov 01 13:31 DSM creates penicillins jv with Harbin, Zhang Jia Kou
- 01 Mar 01 10:33 Indian pharma cheers R&D measures in '01 budget
- 26 Feb 01 15:22 India's Max Group to sell Max GB jv share to Dutch DSM
Latest News
- 18 Jun 13 06:54 Integrated production lowers enzyme cost of ethanol
- 18 Jun 13 06:52 Cellulosic ethanol could solve India’s fuel needs, energy security
- 18 Jun 13 06:52 S America presents growth promise for US oil/gas exports -analyst
- 18 Jun 13 06:00 VIDEO - ICIS Asia Lunchtime Bulletin 18 June 2013
- 18 Jun 13 05:29 Asia C3 hits 15-week high; may extend gains on tight supply